دورية أكاديمية
أعرض في EDS

Beneficial effects of Silexan on co-occurring depressive symptoms in patients with subthreshold anxiety and anxiety disorders: randomized, placebo-controlled trials revisited.

التفاصيل البيبلوغرافية
العنوان: Beneficial effects of Silexan on co-occurring depressive symptoms in patients with subthreshold anxiety and anxiety disorders: randomized, placebo-controlled trials revisited.
المؤلفون: Bartova L; Department of Psychiatry and Psychotherapy, Medical University of Vienna, Währinger Gürtel 18-20, 1090, Vienna, Austria., Dold M; Department of Psychiatry and Psychotherapy, Medical University of Vienna, Währinger Gürtel 18-20, 1090, Vienna, Austria., Volz HP; Hospital for Psychiatry, Psychotherapy and Psychosomatic Medicine, Schloss Werneck, Balthasar-Neumann-Platz 1, 97440, Werneck, Germany., Seifritz E; Department of Psychiatry, Psychotherapy, and Psychosomatics, Psychiatric Hospital, University of Zürich, Lenggstrasse 31, 8032, Zürich, Switzerland., Möller HJ; Clinic and Policlinic for Psychiatry and Psychotherapy, Ludwig-Maximilian-University Munich, Nußbaumstraße 7, 80336, Munich, Germany., Kasper S; Department of Psychiatry and Psychotherapy, Medical University of Vienna, Währinger Gürtel 18-20, 1090, Vienna, Austria. siegfried.kasper@meduniwien.ac.at.; Center for Brain Research, Medical University of Vienna, Spitalgasse 4, 1090, Vienna, Austria. siegfried.kasper@meduniwien.ac.at.
المصدر: European archives of psychiatry and clinical neuroscience [Eur Arch Psychiatry Clin Neurosci] 2023 Feb; Vol. 273 (1), pp. 51-63. Date of Electronic Publication: 2022 Mar 09.
نوع المنشور: Meta-Analysis; Journal Article
اللغة: English
بيانات الدورية: Publisher: Springer International Country of Publication: Germany NLM ID: 9103030 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1433-8491 (Electronic) Linking ISSN: 09401334 NLM ISO Abbreviation: Eur Arch Psychiatry Clin Neurosci Subsets: MEDLINE
أسماء مطبوعة: Original Publication: Berlin ; New York : Springer International, c1990-
مواضيع طبية MeSH: Depression*/drug therapy , Anxiety Disorders*/drug therapy, Humans ; Anxiety/drug therapy ; Antidepressive Agents/therapeutic use ; Double-Blind Method ; Treatment Outcome ; Randomized Controlled Trials as Topic
مستخلص: Silexan is a proprietary active substance produced from Lavandula angustifolia, with proven anxiolytic efficacy in subthreshold and generalized anxiety disorder as well as in mixed anxiety and depressive disorder with beneficial impact on anxiety-related sleep disturbances. The pharmacological profile and clinical observations suggest that Silexan may also have an antidepressant effect. To investigate the effect of Silexan on co-occurring depressive symptoms, we present a meta-analysis of the five placebo-controlled clinical trials hitherto performed with Silexan in subthreshold anxiety (n = 3) and anxiety disorders (n = 2). Patients of all trials received Silexan 1 × 80 mg/day or placebo for 10 weeks according to random assignment. Assessment of the antidepressant effect was based on item 'depressed mood' from the Hamilton Anxiety Rating Scale (HAMA) administered in all trials and on the total scores of the Montgomery Åsberg Depression Rating Scale (MADRS) or the Hamilton Depression Rating Scale (HAMD) used in three trials. After 10-week treatment, patients receiving Silexan showed significantly more pronounced score reduction for HAMA item 'depressed mood' than those in the placebo group (p = 0.01). Significant superiority of Silexan over placebo could also be shown for mean MADRS or HAMD total score reduction (three studies; p < 0.01). Silexan-treated patients with more severe depressive symptoms at baseline showed more pronounced improvements than those with milder symptoms. Our meta-analysis clearly shows that Silexan has a beneficial effect on co-occurring depressive symptoms in patients with subthreshold anxiety and anxiety disorders and may, hence, lead to important therapeutic implications for depressive disorders.
(© 2022. The Author(s).)
References: Eur Neuropsychopharmacol. 2016 Feb;26(2):331-340. (PMID: 26718792)
Eur Arch Psychiatry Clin Neurosci. 2019 Mar;269(2):183-193. (PMID: 29150713)
Br J Psychiatry. 1979 Apr;134:382-9. (PMID: 444788)
BMC Psychiatry. 2014 May 01;14:128. (PMID: 24886240)
Neurochem Int. 2021 Feb;143:104899. (PMID: 33181239)
Lancet Psychiatry. 2017 May;4(5):409-418. (PMID: 28153641)
Asian Nurs Res (Korean Soc Nurs Sci). 2019 Dec;13(5):295-305. (PMID: 31743795)
Complement Ther Med. 2014 Feb;22(1):63-9. (PMID: 24559818)
J Psychiatr Res. 2017 Aug;91:1-13. (PMID: 28284107)
Brain Behav. 2021 Apr;11(4):e01997. (PMID: 33638614)
Acta Psychiatr Scand. 2017 Oct;136(4):341-342. (PMID: 28865404)
Lancet. 2013 Nov 9;382(9904):1575-86. (PMID: 23993280)
Neurochem Int. 2011 Aug;59(2):138-49. (PMID: 21689704)
J Affect Disord. 2013 Sep 5;150(2):384-8. (PMID: 23759278)
J Nerv Ment Dis. 1969 Jan;148(1):87-98. (PMID: 5768895)
Int J Neuropsychopharmacol. 2014 Oct 31;18(4):. (PMID: 25522403)
PLoS One. 2013 Apr 29;8(4):e59998. (PMID: 23637742)
Behav Res Methods. 2013 Jun;45(2):576-94. (PMID: 23055166)
Sci Rep. 2019 Dec 2;9(1):18042. (PMID: 31792285)
Prog Neurobiol. 2009 May;88(1):17-31. (PMID: 19428959)
J Affect Disord. 2017 Jul;216:123-135. (PMID: 27554605)
Br J Psychiatry. 1986 May;148:599-601. (PMID: 3779233)
Arch Gen Psychiatry. 2005 Jun;62(6):617-27. (PMID: 15939839)
Evid Based Complement Alternat Med. 2020 Jul 14;2020:5418586. (PMID: 32733584)
World J Biol Psychiatry. 2019 Jul;20(6):427-448. (PMID: 31340696)
Eur Neuropsychopharmacol. 2015 Nov;25(11):1960-7. (PMID: 26293583)
Lancet Psychiatry. 2015 Jun;2(6):515-23. (PMID: 26360447)
J Anxiety Disord. 2017 Mar;46:56-64. (PMID: 27707524)
J Psychiatr Res. 2019 Aug;115:69-74. (PMID: 31121394)
Br J Soc Clin Psychol. 1967 Dec;6(4):278-96. (PMID: 6080235)
Phytomedicine. 2019 Dec;65:153099. (PMID: 31655395)
Psychol Med. 2016 Dec;46(16):3359-3369. (PMID: 27623748)
Nat Med. 2016 Mar;22(3):238-49. (PMID: 26937618)
J Ethnopharmacol. 2012 Sep 28;143(2):673-9. (PMID: 22867633)
Acta Psychiatr Scand. 1983 Jun;67(6):361-70. (PMID: 6880820)
Int J Psychiatry Clin Pract. 2012 Jun;16(2):77-84. (PMID: 22540422)
Acta Psychiatr Scand. 2021 Jan;143(1):36-49. (PMID: 33141944)
Eur Arch Psychiatry Clin Neurosci. 2016 Dec;266(8):725-736. (PMID: 27002521)
Arch Gen Psychiatry. 2005 Jun;62(6):593-602. (PMID: 15939837)
Depress Anxiety. 2021 Mar;38(3):286-306. (PMID: 33225514)
Int Clin Psychopharmacol. 2019 May;34(3):110-118. (PMID: 30870236)
Int J Epidemiol. 2014 Apr;43(2):476-93. (PMID: 24648481)
Pharmacopsychiatry. 2021 Jan;54(1):37-46. (PMID: 33254260)
Stat Med. 2017 Feb 28;36(5):855-875. (PMID: 27747915)
Depress Anxiety. 2000;12 Suppl 1:2-19. (PMID: 11098410)
Eur Neuropsychopharmacol. 2011 Sep;21(9):655-79. (PMID: 21896369)
Int Clin Psychopharmacol. 2000 Aug;15 Suppl 2:S41-5. (PMID: 11110018)
Psychol Bull. 2017 Nov;143(11):1155-1200. (PMID: 28805400)
Eur Arch Psychiatry Clin Neurosci. 2019 Mar;269(2):145-146. (PMID: 30680488)
Int J Neuropsychopharmacol. 2014 Jun;17(6):859-69. (PMID: 24456909)
Biol Psychiatry. 2009 Oct 1;66(7):627-35. (PMID: 19423077)
Int Clin Psychopharmacol. 2017 Jul;32(4):195-204. (PMID: 28379882)
Br J Med Psychol. 1959;32(1):50-5. (PMID: 13638508)
J Clin Psychiatry. 1997;58 Suppl 8:20-6. (PMID: 9236732)
BMJ. 2010 Feb 05;340:c221. (PMID: 20139215)
Acta Psychiatr Scand. 2019 Jan;139(1):78-88. (PMID: 30291625)
Emotion. 2012 Feb;12(1):58-68. (PMID: 22309734)
Gen Hosp Psychiatry. 2020 May - Jun;64:33-40. (PMID: 32088511)
World J Biol Psychiatry. 2018 Sep;19(6):412-420. (PMID: 28511598)
Int Clin Psychopharmacol. 2010 Sep;25(5):277-87. (PMID: 20512042)
فهرسة مساهمة: Keywords: Anxiety disorders; Depression; Effects; Lavender; Meta-analysis; Silexan; Subthreshold anxiety
المشرفين على المادة: ZBP1YXW0H8 (lavender oil)
0 (Antidepressive Agents)
تواريخ الأحداث: Date Created: 20220309 Date Completed: 20230228 Latest Revision: 20230228
رمز التحديث: 20240628
مُعرف محوري في PubMed: PMC9958187
DOI: 10.1007/s00406-022-01390-z
PMID: 35262795
قاعدة البيانات: MEDLINE
الوصف
تدمد:1433-8491
DOI:10.1007/s00406-022-01390-z